Barbora Staňková

Barbora Staňková

Auto-generated profile, based on publicly available information

Barbora Staňková

4th Department of Medicine-Department of Gastroenterology and Hepatology, First Faculty of Medicine, Charles University in Prague, 128 00 Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Biomedical Papers
Verified
Journal Article
Open access
PDF file
ETEva Tvrzicka
Eva Tvrzicka
LKLefkothea-Stella Kremmyda
Lefkothea-Stella Kremmyda
BSBarbora Stankova
Barbora Stankova
AZAles Zak
Ales Zak
Background: Fatty acids are substantial components of lipids and cell membranes in the form of phospholipids. This review consists of two parts. The present part aims at describing fatty acid classification, dietary sources and biological func...

11 June 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MRMartin Rossmeisl
Martin Rossmeisl
ZJZuzana Macek Jilkova
Zuzana Macek Jilkova
OKOndrej Kuda
Ondrej Kuda
TJTomas Jelenik
Tomas Jelenik
DMDasa Medrikova
Dasa Medrikova
JKJan Kopecky
Jan Kopecky
n-3 polyunsaturated fatty acids, namely docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), reduce the risk of cardiovascular disease and can ameliorate many of obesity-associated disorders. We hypothesised that the latter effect will be more pronounced when DHA/EPA is supplemented as phospholipids rather than as triglycerides. In a ‘prevention study’, C57BL/6J mice were fed for 9 weeks on either a corn oil-based high-fat obesogenic diet (cHF; lipids ∼35% wt/wt), or cHF-based diets in which corn oil was partially replaced by DHA/EPA, admixed either as phospholipids or triglycerides from marine fish. The reversal of obesity was studied in mice subjected to the preceding cHF-feeding for 4 months. DHA/EPA administered as phospholipids prevented glucose intolerance and tended to reduce obesity better than triglycerides. Lipemia and hepatosteatosis were suppressed more in response to dietary phospholipids, in correlation with better bioavailability of DHA and EPA, and a higher DHA accumulation in the liver, white adipose tissue (WAT), and muscle phospholipids. In dietary obese mice, both DHA/EPA concentrates prevented a further weight gain, reduced plasma lipid levels to a similar extent, and tended to improve glucose tolerance. Importantly, only the phospholipid form reduced plasma insulin and adipocyte hypertrophy, while being more effective in reducing hepatic steatosis and low-grade inflammation of WAT. These beneficial effects were correlated with changes of endocannabinoid metabolome in WAT, where phospholipids reduced 2-arachidonoylglycerol, and were more effective in increasing anti-inflammatory lipids such as N-docosahexaenoylethanolamine. Compared with triglycerides, dietary DHA/EPA administered as phospholipids are superior in preserving a healthy metabolic profile under obesogenic conditions, possibly reflecting better bioavalability and improved modulation of the endocannabinoid system activity in WAT.

1 September 2009 in Clinical Biochemistry
Verified
Journal Article
Closed access
JKJana Kodydková
Jana Kodydková
LVLucie Vávrová
Lucie Vávrová
MZMiroslav Zeman
Miroslav Zeman
RJRoman Jirák
Roman Jirák
JMJaroslav Macášek
Jaroslav Macášek
AŽAleš Žák
Aleš Žák

1 September 2011 in Biomedical Papers
Verified
Journal Article
Open access
PDF file
LKLefkothea-Stella Kremmyda
Lefkothea-Stella Kremmyda
ETEva Tvrzicka
Eva Tvrzicka
BSBarbora Stankova
Barbora Stankova
AZAles Zak
Ales Zak
Background: This is the second of two review parts aiming at describing the major physiological roles of fatty acids, as well as their applications in specific conditions related to human health. Results: The review included the current litera...

24 August 2009 in Proceedings of the Nutrition Society
Verified
Journal Article
Closed access
JKJan Kopecky
Jan Kopecky
MRMartin Rossmeisl
Martin Rossmeisl
PFPavel Flachs
Pavel Flachs
OKOndrej Kuda
Ondrej Kuda
PBPetr Brauner
Petr Brauner
MBMorten Bryhn
Morten Bryhn
Adipose tissue has a key role in the development of metabolic syndrome (MS), which includes obesity, type 2 diabetes, dyslipidaemia, hypertension and other disorders. Systemic insulin resistance represents a major factor contributing to the development of MS in obesity. The resistance is precipitated by impaired adipose tissue glucose and lipid metabolism, linked to a low-grade inflammation of adipose tissue and secretion of pro-inflammatory adipokines. Development of MS could be delayed by lifestyle modifications, while both dietary and pharmacological interventions are required for the successful therapy of MS. Then-3 long-chain (LC) PUFA, EPA and DHA, which are abundant in marine fish, act as hypolipidaemic factors, reduce cardiac events and decrease the progression of atherosclerosis. Thus,n-3 LC PUFA represent healthy constituents of diets for patients with MS. In rodentsn-3 LC PUFA prevent the development of obesity and impaired glucose tolerance. The effects ofn-3 LC PUFA are mediated transcriptionally by AMP-activated protein kinase and by other mechanisms.n-3 LC PUFA activate a metabolic switch toward lipid catabolism and suppression of lipogenesis, i.e. in the liver, adipose tissue and small intestine. This metabolic switch improves dyslipidaemia and reduces ectopic deposition of lipids, resulting in improved insulin signalling. Despite a relatively low accumulation ofn-3 LC PUFA in adipose tissue lipids, adipose tissue is specifically linked to the beneficial effects ofn-3 LC PUFA, as indicated by (1) the prevention of adipose tissue hyperplasia and hypertrophy, (2) the induction of mitochondrial biogenesis in adipocytes, (3) the induction of adiponectin and (4) the amelioration of adipose tissue inflammation byn-3 LC PUFA.

1 January 2006 in Physiological Research
Verified
Journal Article
Closed access
MKMarie Kunesova
Marie Kunesova
RBR Braunerová
R Braunerová
PHP Hlavatý
P Hlavatý
ETE Tvrzická
E Tvrzická
BSB Staňková
B Staňková
ŠSŠ Svačina
Š Svačina
Polyunsaturated fatty acids of n-3 series (n-3 PUFA) were shown to increase basal fat oxidation in humans. The aim of the study was to compare the effect of n-3 PUFA added to a very low calorie diet (VLCD), with VLCD only during three-week inpatient weight reduction. Twenty severely obese women were randomly assigned to VLCD with n-3 PUFA or with placebo. Fatty acids in serum lipid fractions were quantified by gas chromatography. Differences between the groups were determined using ANOVA. Higher weight (7.55+/-1.77 vs. 6.07+/-2.16 kg, NS), BMI (2.82+/-0.62 vs. 2.22+/-0.74, p<0.05) and hip circumference losses (4.8+/-1.81 vs. 2.5+/-2.51 cm, p<0.05) were found in the n-3 group as compared to the control group. Significantly higher increase in beta-hydroxybutyrate was found in the n-3 group showing higher ketogenesis and possible higher fatty acid oxidation. The increase in beta-hydroxybutyrate significantly correlated with the increase in serum phospholipid arachidonic acid (20:4n-6; r = 0.91, p<0.001). In the n-3 group significantly higher increase was found in n-3 PUFA (eicosapentaenoic acid, 20:5n-3, docosahexaenoic acid, 22:6n-3) in triglycerides and phospholipids. The significant decrease of palmitoleic acid (16:1n-7) and vaccenic acid (18:1n-7) in triglycerides probably reflected lower lipogenesis. A significant negative correlation between BMI change and phospholipid docosahexaenoic acid change was found (r = -0.595, p<0.008). The results suggest that long chain n-3 PUFA enhance weight loss in obese females treated by VLCD. Docosahexaenoate (22:6n-3) seems to be the active component.